Logo

PharmaShots Weekly Snapshots (December 20 - 23, 2021)

Share this

PharmaShots Weekly Snapshots (December 20 - 23, 2021)

Novartis’ Cosentyx Receives the US FDA’s Approval to Treat Enthesitis-Related Arthritis and Psoriatic Arthritis

Published: Dec 23, 2021 | Tags: Novartis, Cosentyx, US FDA, Enthesitis-Related Arthritis, Psoriatic Arthritis, Sensoready, US, China

Gilead Reports Full Results from a P-III Investigational Study of Veklury (remdesivir) for the Treatment of COVID-19

Published: Dec 23, 2021 | Tags: Gilead, Veklury, Remdesivir, COVID-19, P-III, PINETREE Study, IND, US, FDA

DURECT Corporation Enters a $136M Licensing Agreement with Innocoll Biotherapeutics for Posimir (Bupivacaine Solution)

Published: Dec 23, 2021 | Tags: DURECT, Innocoll, Posimir, Bupivacaine Solution, US, Commercial Licensing Agreement

Aerogen Pharma Enters an Exclusive Agreement with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China

Published: Dec 23, 2021 | Tags: Aerogen Pharma, Nuance Pharma, Respiratory Distress Syndrome, AeroFact, Alveofact, Nasal Delivery System, China

Akeso and Dawnrays Biotechnology’s Ebronucimab (PCSK9 mAb) Reports Early Completion of Patient Enrollment in P-III Trial for Primary Hypercholesterolemia and Mixed Hyperlipidemia

Published: Dec 23, 2021 | Tags: Akeso, Dawnrays Biotechnology, Ebronucimab, PCSK9 mAb, P-III Trial, Hypercholesterolemia, Mixed Hyperlipidemia

Pfizer Receives the US FDA Emergency Use Authorization for Paxlovid to Treat Mild-to-Moderate COVID-19 in Adults and Pediatric Patients

Published: Dec 23, 2021 | Tags: Pfizer, US FDA, Emergency Use Authorization, Paxlovid, COVID-19, EPIC-HR study, Nirmatrelvir, Ritonavir

Pfizer Reports Five-Year Follow-Up Data of Vyndaqel/Vyndamax in P-III (ATTR-ACT) Trial for Transthyretin Amyloid Cardiomyopathy

Published: Dec 22, 2021 | Tags: Pfizer, Vyndaqel, Vyndamax, P-III, ATTR-ACT Trial, Transthyretin Amyloid Cardiomyopathy

Novartis to Acquire Gyroscope Therapeutics for Ocular Gene Therapy to Treat Geographic Atrophy

Published: Dec 22, 2021 | Tags: Novartis, Acquire, Gyroscope Therapeutics, Ocular Gene Therapy, Geographic Atrophy

Gilead Reports the US FDA's Clinical Hold of Lenacapavir for the Treatment of HIV

Published: Dec 22, 2021 | Tags: Gilead, US, FDA, Clinical Hold, Lenacapavir, HIV

Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease

Published: Dec 22, 2021 | Tags: Novaliq, CyclASol, P-III, ESSENCE-2 Trial, Dry Eye Disease

GSK Expands its Collaboration with Ligand to Develop Genetically-Validated Targets for Neurological Diseases Gilead, US, FDA, Clinical Hold, Lenacapavir, HIV

Published: Dec 22, 2021 | Tags: GSK, Ligand, Genetically-Validated, Targets, Neurological Diseases

Karyopharm Signs an Exclusive License Agreement with Menarini to Commercialize Nexpovio (selinexor) for Oncology

Published: Dec 22, 2021 | Tags: Karyopharm, Menarini, Nexpovio, Selinexor, Oncology

Gilead’s Veklury (remdesivir) Receives EC’s Approval for the Treatment of COVID-19

Published: Dec 21, 2021 | Tags: Gilead, Veklury, remdesivir, EC, Approval, COVID-19

Lilly Reports Results of Lebrikizumab in P-III (Adhere) Trial for the Treatment of Atopic Dermatitis

Published: Dec 21, 2021 | Tags: Lilly, Lebrikizumab, P-III, Adhere Trial, Atopic Dermatitis

Sanofi to Acquire Amunix for Transformative T-Cell Engagers and Cytokine Therapies to Treat Cancer

Published: Dec 21, 2021 | Tags: Sanofi, Acquire, Amunix, Transformative T-Cell Engagers, Cytokine Therapies, Cancer

ViiV Healthcare’s Apretude (cabotegravir) Receives US FDA’s Approval for the Prevention of HIV

Published: Dec 21, 2021 | Tags: ViiV Healthcare, Apretude, cabotegravir, US, FDA, Approval, HIV

Cytokinetics Expands its Collaboration with Ji Xing to Develop and Commercialize Omecamtiv Mecarbil for HFrEF in Greater China

Published: Dec 21, 2021 | Tags: Cytokinetics, Ji Xing, Omecamtiv Mecarbil, HFrEF, Greater China

Novartis Signs a Multiple Agreement with BeiGene for Ociperlimab to Treat Solid Tumor

Published: Dec 21, 2021 | Tags: Novartis, BeiGene, Ociperlimab, Solid Tumor

Lineage Signs an Exclusive WW Agreement with Genentech to Develop and Commercialize OpRegen RPE Cell Therapy for the Treatment of Ocular Disorders

Published: Dec 20, 2021 | Tags: Lineage, Genentech, OpRegen RPE Cell Therapy, Ocular Disorders

Novartis Reports Update of ligelizumab (QGE031) in P-III PEARL 1 & 2 Studies for the Treatment of Chronic Spontaneous Urticaria

Published: Dec 20, 2021 | Tags: Novartis, Ligelizumab, QGE031, P-III, PEARL 1, 2, Studies, Chronic Spontaneous Urticaria

Bluebird bio Reports US FDA Acceptance of BLA for Priority Review of Lenti-D (elivaldogene autotemcel) for Cerebral Adrenoleukodystrophy

Published: Dec 20, 2021 | Tags: bluebird bio, US, FDA, BLA, Priority Review, Lenti-D, elivaldogene autotemcel, Cerebral Adrenoleukodystrophy

GBT’s Oxbryta (voxelotor) Receives CHMP Positive Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease

Published: Dec 20, 2021 | Tags: GBT, Oxbryta, voxelotor, CHMP, Hemolytic Anemia, Sickle Cell Disease

GSK and Vir’s Xevudy (sotrovimab) Receive EC's Marketing Authorization for the Treatment of COVID-19

Published: Dec 20, 2021 | Tags: GSK, Vir, Xevudy, sotrovimab, EC, Marketing Authorization, COVID-19

Janssen Signs a Multiple Agreement with Dyadic to Manufacture Therapeutic Protein Candidates Using C1 Platform

Published: Dec 20, 2021 | Tags: Janssen, Dyadic, Therapeutic Protein Candidates, C1 Platform

Related Post: PharmaShots Weekly Snapshots (December 13 - 17, 2021)

 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions